Valneva SE (VLA) | Financial Analysis & Statements
Valneva SE Mid-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
47.7M
Gross Profit
11.6M
24.36%
Operating Income
-27.7M
-58.06%
Net Income
-50.0M
-104.89%
Balance Sheet Metrics
Total Assets
398.8M
Total Liabilities
292.7M
Shareholders Equity
106.2M
Debt to Equity
2.76
Cash Flow Metrics
Operating Cash Flow
-61.1M
Free Cash Flow
-25.6M
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Valneva SE Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 174.7M | 169.6M | 153.7M | 361.3M | 348.1M |
| Cost of Goods Sold | 107.1M | 98.5M | 100.9M | 324.4M | 187.9M |
| Gross Profit | 67.5M | 71.0M | 52.8M | 36.9M | 160.2M |
| Gross Margin % | 38.7% | 41.9% | 34.4% | 10.2% | 46.0% |
| Operating Expenses | |||||
| Research & Development | 85.3M | 74.1M | 59.9M | 104.9M | 173.3M |
| Selling, General & Administrative | 74.7M | 95.1M | 96.6M | 57.6M | 71.2M |
| Other Operating Expenses | -11.2M | -20.8M | -22.0M | -12.5M | -23.2M |
| Total Operating Expenses | 148.8M | 148.5M | 134.5M | 150.0M | 221.3M |
| Operating Income | -81.6M | -77.8M | -82.1M | -113.4M | -61.3M |
| Operating Margin % | -46.7% | -45.9% | -53.4% | -31.4% | -17.6% |
| Non-Operating Items | |||||
| Interest Income | 1.8M | 2.4M | 1.2M | 260.0K | 249.0K |
| Interest Expense | 41.9M | 24.0M | 23.3M | 19.1M | 17.0M |
| Other Non-Operating Income | 6.8M | 87.9M | 5.6M | -12.6M | 8.1M |
| Pre-tax Income | -114.1M | -11.5M | -98.6M | -144.8M | -70.0M |
| Income Tax | 1.1M | 761.0K | 2.8M | -1.5M | 3.4M |
| Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Income | -115.2M | -12.2M | -101.4M | -143.3M | -73.4M |
| Net Margin % | -66.0% | -7.2% | -66.0% | -39.7% | -21.1% |
| Key Metrics | |||||
| EBITDA | -57.2M | 35.0M | -63.3M | -92.1M | -46.8M |
| EPS (Basic) | €-0.68 | €-0.08 | €-0.73 | €-1.24 | €-0.75 |
| EPS (Diluted) | €-0.68 | €-0.08 | €-0.73 | €-1.24 | €-0.75 |
| Basic Shares Outstanding | 168179263 | 145705876 | 138943836 | 115547581 | 97619320 |
| Diluted Shares Outstanding | 168179263 | 145705876 | 138943836 | 115547581 | 97619320 |
Income Statement Trend
Valneva SE Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 109.6M | 168.3M | 126.1M | 286.5M | 346.6M |
| Short-term Investments | - | - | - | - | - |
| Accounts Receivable | 27.7M | 35.2M | 41.6M | 23.9M | 44.0M |
| Inventory | 50.2M | 53.7M | 44.5M | 35.1M | 124.1M |
| Other Current Assets | 34.8M | 41.9M | 50.6M | 74.1M | 71.0M |
| Total Current Assets | 222.5M | 299.0M | 262.8M | 424.7M | 585.8M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 76.3M | 74.7M | 136.4M | 112.7M | 44.4M |
| Goodwill | 22.3M | 25.3M | 25.6M | 28.7M | 32.7M |
| Intangible Assets | 22.3M | 25.3M | 25.6M | 28.7M | 32.7M |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 15.9M | 17.6M | 15.1M | 13.9M | 22.9M |
| Total Non-Current Assets | 176.3M | 201.0M | 197.2M | 196.7M | 231.5M |
| Total Assets | 398.8M | 500.0M | 460.1M | 621.3M | 817.4M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 9.1M | 12.6M | 17.6M | 14.5M | 16.0M |
| Short-term Debt | 20.6M | 23.4M | 47.0M | 37.0M | 10.2M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 5.7M | 5.2M | 592.0K | 5.5M | 5.0M |
| Total Current Liabilities | 93.3M | 114.6M | 158.9M | 277.4M | 369.0M |
| Non-Current Liabilities | |||||
| Long-term Debt | 186.6M | 193.0M | 161.9M | 115.4M | 104.4M |
| Deferred Tax Liabilities | 4.4M | 4.2M | 3.6M | 694.0K | 1.3M |
| Other Non-Current Liabilities | 245.0K | 48.0K | 79.0K | 115.0K | 70.0K |
| Total Non-Current Liabilities | 199.3M | 204.2M | 173.0M | 124.2M | 277.8M |
| Total Liabilities | 292.7M | 318.8M | 331.8M | 401.5M | 646.8M |
| Equity | |||||
| Common Stock | 26.0M | 24.4M | 20.8M | 20.8M | 15.8M |
| Retained Earnings | -679.1M | -563.9M | -551.7M | -450.3M | -307.0M |
| Treasury Stock | 645.0K | 645.0K | 645.0K | 645.0K | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 106.2M | 181.3M | 128.2M | 219.8M | 170.6M |
| Key Metrics | |||||
| Total Debt | 207.2M | 216.3M | 208.8M | 152.4M | 114.7M |
| Working Capital | 129.2M | 184.4M | 104.0M | 147.3M | 216.9M |
Balance Sheet Composition
Valneva SE Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -115.2M | -12.2M | -101.4M | -143.3M | -73.4M |
| Depreciation & Amortization | 21.8M | 19.6M | 17.6M | 21.0M | 14.3M |
| Stock-Based Compensation | 9.5M | 8.0M | 5.1M | -8.7M | 14.5M |
| Working Capital Changes | 4.3M | -8.3M | -127.7M | -131.9M | 60.2M |
| Operating Cash Flow | -48.1M | 30.3M | -182.3M | -231.5M | 24.2M |
| Investing Activities | |||||
| Capital Expenditures | -4.3M | -13.7M | -14.1M | -29.2M | -92.2M |
| Acquisitions | 0 | 0 | -11.0M | 0 | 0 |
| Investment Purchases | - | - | - | - | - |
| Investment Sales | 841.0K | - | - | - | - |
| Investing Cash Flow | -3.5M | 77.1M | -21.7M | -29.2M | -92.2M |
| Financing Activities | |||||
| Share Repurchases | - | - | -240.0K | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Debt Issuance | 174.4M | - | 81.1M | 39.3M | 859.0K |
| Debt Repayment | -174.3M | -6.5M | -5.2M | -4.8M | -4.8M |
| Financing Cash Flow | 62.0K | -6.5M | 75.6M | 224.3M | 162.9M |
| Free Cash Flow | -57.4M | -83.7M | -217.1M | -274.7M | -16.3M |
| Net Change in Cash | -51.5M | 101.0M | -128.4M | -36.4M | 94.9M |
Cash Flow Trend
Valneva SE Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
70.64
Forward P/E
8.67
Price to Book
3.91
Price to Sales
2.38
PEG Ratio
8.67
Profitability Ratios
Profit Margin
-65.95%
Operating Margin
-58.05%
Return on Equity
-80.16%
Return on Assets
-11.35%
Financial Health
Current Ratio
2.38
Debt to Equity
195.21
Beta
1.53
Per Share Data
EPS (TTM)
€-0.68
Book Value per Share
€0.61
Revenue per Share
€1.04
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| VLA | 416.1M | 70.64 | 3.91 | -80.16% | -65.95% | 195.21 |
| Abivax SA | 7.6B | -19.88 | 16.56 | -135.58% | 0.00% | 7.05 |
| Nanobiotix | 1.4B | - | - | 28.36% | -73.52% | -1.13 |
| Medincell S.A | 831.6M | -37.35 | - | 112.65% | -61.49% | -2.40 |
| BNP Paribas Easy | 527.3M | 22.65 | - | -96.39% | -27.22% | 2.22 |
Financial data is updated regularly. All figures are in the company's reporting currency.